Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. BIESF.PINK

Biotest Aktiengesellschaft (BIESF PINK) stock market data APIs

$30.48 0(0%) as of July 25, 2024
Price chart is built with Anychart

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Biotest Aktiengesellschaft Financial Data Overview

30.48
30.48
-
30.48
30.48
28.7394-34.5512
1 429 M
6.3106
19 786 K
783 M
0.0014
0.237
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BIESF',
Type: 'Common Stock',
Name: 'Biotest Aktiengesellschaft',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BW2PW3',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Biotest Aktiengesellschaft Fundamental Data is available in our Financial Data APIs

  • Net Revenue 783 M
  • EBITDA 209 M
  • Earnings Per Share 4.83
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Biotest Aktiengesellschaft Earnings via APIs

  • Latest Release 2024-07-30
  • EPS/Forecast NaN

Get Biotest Aktiengesellschaft End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Biotest Aktiengesellschaft latest news via APIs

Creat Said to Near Sale of Blood Plasma Firm Biotest to Grifols

(Bloomberg) -- China’s Creat Group Corp. is nearing the sale of German blood-plasma supplier Biotest AG to Grifols SA of Spain, according to people familiar with the matter. The companies could ann...
  • BIOTEST
  • BIOTEST AG
  • BLOOD PLASMA
  • BLOOMBERG
  • BLOOMBERG NEWS
  • CHINA’S CREAT GROUP CORP
  • GRIFOLS

Advent, Fresenius Vie for Creat’s Blood Plasma Business

(Bloomberg) -- Chinese pharmaceutical group Creat Group Corp. is drawing interest from a mix of private equity firms and strategic suitors as it explores a sale of its blood-plasma supply businesses i...
  • BAIN CAPITAL
  • BIOTEST AG AND BIO PRODUCTS LABORATORY LTD
  • BLOOD PLASMA
  • BLOOMBERG
  • CREAT GROUP CORP
  • PRIVATE EQUITY FIRMS
Do you have any questions?
support@eodhistoricaldata.com